The ‘Fictitious Disease’ Called ADHDPosted: October 29, 2016
The ADHD Scam and the Mass Drugging of School Children
“ADHD is a prime example of a fictitious disease.”
These were the words of Leon Eisenberg, the ‘father of ADHD (Attention Deficit Hyperactivity Disorder),’ in his final interview before he died in 2009 at 87 years of age. Some have described Dr. Eisenberg’s statement as an ‘exaggeration’ of sorts however many doctors are now coming to the realization that ADHD is often ‘over diagnosed’.
Let’s go back 50 years. We have a 7-year-old child who is bored in school and disrupts classes. Back then, he was called lazy. Today, he is said to suffer from ADHD (Attention Deficit Hyperactivity Disorder). . . . Every child who’s not doing well in school is sent to see a pediatrician, and the pediatrician says: “It’s ADHD; here’s Ritalin.
Dr Eisenberg made a excellent and often luxurious living off of his “fictitious disease,” thanks to pharmaceutical sales.
He received the Ruane Prize for Child and Adolescent Psychiatry Research and was a leader in child psychiatry for more than 40 years through his work in pharmacological trials, research, teaching, and social policy and for his theories of autism and social medicine.
In the United States, 1 out of 10 boys among 10-year-olds takes medication for ADHD on a daily basis . . . with increasing tendency.
American psychologist Lisa Cosgrove and others reveal the facts in their study “Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry.” They found that “of the 170 DSM panel members 95 (56 percent) had one or more financial associations with companies in the pharmaceutical industry. One hundred percent of the members of the panels on ‘Mood Disorders’ and ‘Schizophrenia and Other Psychotic Disorders’ had financial ties to drug companies.”
And they are reaping major benefits from this “fictitious disease.” For example, the assistant director of the Pediatric Psychopharmacology Unit at Massachusetts General Hospital and associate professor of Psychiatry at Harvard Medical School received “$1 million in earnings from drug companies between 2000 and 2007.”
Marc-André Gagnon and Joel Lexchin, a long-time researcher of pharmaceutical promotion, performed a study which shows that the U.S. pharmaceutical industry spent 24.4 percent of the sales dollar on promotion, versus 13.4 percent for research and development in 2004. That is almost twice as much money to push their drugs on people than the amount to research to make sure it they’re safe!